Polymorphisms within Genes Coding for IL-17A and F and Their Receptor as Clinical Hallmarks in Ankylosing Spondylitis
Table 1
Clinical characteristics of the study cohort.
Characteristic
Median (range)
Age (years)
138
43.5 (22-75)
Disease duration (years)
135
10 (0-48)
Disease onset (years)
135
33 (6-56)
BMI
113
25.32 (18.61-40.31)
CRP before treatment (mg/l)
108
16.83 (0.3-561)
CRP at 3 months (mg/l)
79
5.75 (0.2-175)
CRP at 6 months (mg/l)
72
5.495 (0.2-204.3)
VAS before treatment (mm)
132
80 (45-100)
VAS at 3 months (mm)
138
30 (0-80)
VAS at 6 months (mm)
131
20 (0-100)
BASDAI before treatment
138
8 (4.05-10)
BASDAI at 3 months
138
3.2 (0.7-6.7)
BASDAI at 6 months
132
2.25 (0.2-9.75)
Treatment (anti-TNF drug)
(%)
Adalimumab
63 (45.6%)
Etanercept
44 (31.9%)
Certolizumab
17 (12.3%)
Golimumab
12 (8.69%)
Infliximab
2 (1.45%)
: number of patients with clinical information; BMI: body mass index; CRP: C-reactive protein; MTX: methotrexate; NSAIDs: nonsteroidal anti-inflammatory drugs; BASDAI: Bath Ankylosing Spondylitis Disease Activity Index; VAS: visual analogue scale; HLA-B27: human leukocyte antigen B27. ; value comparing the clinical variables between baseline and after 3 or 6 months of treatment.
